Trial Profile
A phase 1, single- and repeated-dose, randomized, open-label, multi-center study to evaluate the pharmacokinetics, pharmacodynamics and safety of lansoprazole in neonates with clinically-evident gastroesophageal reflux disease.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Lansoprazole (Primary)
- Indications Gastro-oesophageal reflux
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Takeda
- 05 Nov 2005 New trial record.